New phase 3 and 4 trials: 60 in the week of Oct. 12, against a median of 80
ClinicalTrials.gov recorded 60 new phase 3 and 4 trials in the week of Oct. 12, 2026, compared with a median of 80 over the 16 earlier weeks.
Phase 3 and 4 trials are later-stage human studies used to test whether a treatment works and how it performs in wider use, so their weekly count tracks late-stage testing activity.
ClinicalTrials.gov listed 60 new phase 3 and phase 4 trials for the week of Oct. 12, 2026, Monday through Sunday; the source marks the data complete through Oct. 24, 2026. The baseline is a median of 80 new trials a week over 16 earlier weeks, according to the same ClinicalTrials.gov data.
Phase 3 trials are larger human studies that test whether an intervention works; phase 4 trials study treatments in wider use after approval. Registering a trial on ClinicalTrials.gov is a form of preregistration, recording the study plan; the weekly count measures new registrations, not completed studies or results.
One record in the week was NCT07877818, sponsored by AstraZeneca, for a study of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in Chinese patients with resectable GC/GEJC.
Room for disagreement
This is a one-week count, so a single week can be a one-off; the median of 80 over 16 earlier weeks does not by itself show a trend.
About the data
Every figure in this story is read from PostNewz's pn_records table (1291 rows read Oct 24, 6:31 a.m. HST): New phase 3 and 4 trials per week; the week of 2026-10-12 holds 60 against a median of 80 over 16 earlier complete weeks (pn_records; complete through 2026-10-24). Prose by Hannah Lowe (pn98-pnj-v8.2, model @cf/deepseek-ai/deepseek-v4.1-flash-1017); numbers checked against the rows by the figure guard; neutrality check passed.